Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context

Autor: Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, D.H. Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce S. Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus S. Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, Shubhangi A. Kanitkar, Arjun L. Kakrani, Srikanth P. Tripathy, Abhijit V. Tilak, Akshay A. Dhamne, Shahzad Beg Mirza, Prachi V. Athavale, Mandakini Bhowmik, Parag J. Ratnakar, Subodh Gupta, Vijayshri Deotale, Jyoti Jain, Ashwini Kalantri, Vineet Jain, Nidhi Goyal, Alok Arya, Temsunaro Rongsen-Chandola, Shreyasi Dasgupta, Pratibha Periera, Vanmathi A, Anand Kawade, Arunkumar Gondhali, Palvi Kudyar, Abhishek Singh, Ravi Yadav, Alina Alexander, Venugopalan Gunasekaran, Sekar Dineshbabu, P.C. Samantaray, H.S. Ravish, Deepshikha Kamra, Shilpa Gaidhane, Quazi Syed Zahiruddin, Merlin Moni, Anil Kumar, Ameet Dravid, Anant Mohan, Tejas Suri, Tejas K. Patel, Surekha Kishore, Rahul Choche, Deepak Ghatage, Sugam Salvi

Publikováno v: The Lancet Regional Health - Southeast Asia, Vol 10, Iss , Pp 100139- (2023)

Summary: Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study

Externí odkaz: https://doaj.org/article/82d9dafd89e042aabbf3940c237b71b1

Impact of suspected adverse drug reactions on mortality and length of hospital stay in the hospitalised patients: a meta-analysis

Autor: Tejas K. Patel, Parvati B. Patel, Hira Lal Bhalla, Priyanka Dwivedi, Vijeta Bajpai, Surekha Kishore

Publikováno v: European Journal of Clinical Pharmacology. 79:99-116

To estimate the risk of mortality and length of stay in hospitalised patients who have experienced suspected adverse drug reactions (ADRs) as compared to patients who did not experience suspected ADRs.A systematic literature search was conducted on d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5d64d106d10cae338ebd157a152426
https://doi.org/10.1007/s00228-022-03419-7

Drug-related deaths among inpatients: a meta-analysis

Autor: Tejas K Patel, Surekha Kishore, Parvati B. Patel, Hira Lal Bhalla

Publikováno v: European Journal of Clinical Pharmacology. 78:267-278

PURPOSE To estimate the prevalence of drug-related deaths with regard to total hospital mortality and to explore the heterogeneity in its estimation through subgroup analysis, univariate and multivariate analysis. METHODS Two investigators independen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60a170437827f2389ab879b37b5f3f65
https://doi.org/10.1007/s00228-021-03214-w

Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report

Autor: Hira Lal Bhalla, Abhishek Gupta, Tejas K Patel

Publikováno v: Current Drug Safety. 16:293-295

Background: Xylometazoline, a sympathomimetic agent, is considered safe in hypertensive patients as a relief measure for nasal congestion with intranasal application. Case Report:: In the present case, a 58-year old male patient, having ischemic hear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59a5d74a99ca3df7c174b43a85a84e21
https://doi.org/10.2174/1574886316666210114094856

Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review

Autor: Hira Lal Bhalla, Bhavesh D. Kevadiya, Tejas K Patel, Manish J Barvaliya, Parvati B. Patel

Publikováno v: Journal of Neuroimmune Pharmacology

Hydroxychloroquine has been promoted for its use in treatment of COVID-19 patients based on in-vitro evidences. We searched the databases to include randomized and observational studies evaluating the effect of Hydroxychloroquine on mortality in COVI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec7de2a583815317e2656d299170204